Indian version of Enasidenib price and purchase method

Enasidenib is a targeted drug for acute myeloid leukemia (AML) with mutations in the IDH2 gene. It inhibits the activity of the mutant IDH2 enzyme and reduces the production of abnormal tumor cell metabolism product 2-HG, thereby promoting the differentiation of immature leukemia cells. This differentiated therapy provides new treatment ideas for some patients with relapsed or refractory AML. As an oral small molecule drug, ensidipine was developed in the United States and was the first to be approved for marketing. It is currently sold in many countries such as Europe and the United States. However, in the Indian market, there is no original or generic version of the drug so far, which means that patients cannot directly purchase ensidipine from legal channels in Indian pharmacies.

In the international market, some emerging countries have begun to produce generic drugs of ensidipine. For example, pharmaceutical companies in Laos and other places have launched generic products with a specification of 50mg*30 tablets. The price is about more than 2,000 yuan per box. However, due to exchange rate fluctuations and supply chain differences, the specific price may change. Generic drugs have the same active ingredients as original drugs, which can alleviate patients' financial pressure to a certain extent. Usually, if patients want to purchase overseas versions, they need to go through regular cross-border pharmacies or designated import channels to ensure that the source of the drugs is legal and the quality is reliable. It should be noted that different countries have strict regulations on the import of targeted drugs. Therefore, when patients consider cross-border drug purchases, it is best to consult a doctor in advance and verify the legality of the channel to avoid purchasing substandard or counterfeit drugs.

At present, ensidipine is not available in China, and patients who need to use it can only obtain it through formal overseas channels. With the progress of global drug registration and generic drug development, if more countries approve the listing of generic drugs in the future, the price may be further reduced and the access method will be more convenient. However, at this stage, there is no official version available in the Indian market, and patients should avoid choosing unsafe channels due to"low price promotion".

Reference materials:https://www.idhifa.com/